Acute lymphoblastic leukemia requires around 18 months of daily oral chemotherapy called 6-mercaptopurine (6-MP) for treatment. Previous research has included a broad age range and shows adolescent/young adult (AYA) age and minoritized race/ethnicity are associated with lower adherence. Few studies have evaluated how these intersecting identities impact adherence. In a retrospective analysis of an AYA sample, we evaluated the relationships between race/ethnicity, area deprivation index (ADI), and insurance with electronically monitored 6-MP adherence. Results showed minoritized race/ethnicity and ADI correlated with adherence. Findings highlight the need for equitable interventions that enhance adherence and improve outcomes among AYAs.
Get full access to this article
View all access options for this article.
References
1.
BhatiaS, LandierW, HagemanL, et al.6-MP adherence in a multiracial cohort of children with acute lymphoblastic leukemia: A Children’s Oncology Group Study. Blood, 2014; 124(15):2345–2353; doi: 10.1182/blood-2014-01-552166
2.
BhatiaS, HagemanL, ChenY, et al.A randomized trial of a Mercaptopurine (6-MP) adherence-enhancing intervention in children with Acute Lymphoblastic Leukemia (ALL): A COG ACCL1033 study. J Clin Oncol, 2019; 37(suppl 15):10007; doi: 10.1200/JCO.2019.37.15_suppl.10007
3.
PetridouET, SergentanisTN, PerlepeC, et al.Socioeconomic disparities in survival from childhood leukemia in the United States and globally: A meta-analysis. Ann Oncol, 2015; 26(3):589–597; doi: 10.1093/annonc/mdu572
4.
SiegelRL, MillerKD, JemalA. Cancer statistics, 2020. CA Cancer J Clin, 2020; 70(1):7–30; doi: 10.3322/caac.21590
5.
PsihogiosAM, AhmedA, HolbeinCE, SmithAW. Pediatric treatment adherence. In: Handbook of Pediatric Psychology, Developmental Science, and Developmental and Behavioral Pediatrics. APA.
Nahum-ShaniI, SmithSN, SpringBJ, et al.Just-In-Time Adaptive Interventions (JITAIs) in mobile health: Key components and design principles for ongoing health behavior support. Ann Behav Med, 2018; 52(6):446–462; doi: 10.1007/s12160-016-9830-8
9.
KindAJH, BuckinghamWR. Making neighborhood-disadvantage metrics accessible—the neighborhood atlas. N Engl J Med, 2018; 378(26):2456–2458; doi: 10.1056/NEJMp1802313
OhlsenTJD, DoodyDR, MuellerBA, et al.Population-based impact of rurality and neighborhood-level socioeconomic disadvantage on pediatric cancer mortality in Washington State. Cancer Epidemiol Biomarkers Prev, 2023; 32(1):141–148; doi: 10.1158/1055-9965.EPI-22-0897
PsihogiosAM, LiY, AhmedA, et al.Daily text message assessments of 6‐mercaptopurine adherence and its proximal contexts in adolescents and young adults with leukemia: A Pilot Study. Pediatr Blood Cancer, 2021; 68(2):e28767; doi: 10.1002/pbc.28767
15.
RohanJM, FukudaT, AlderferMA, et al.Measuring medication adherence in pediatric cancer: An approach to validation. J Pediatr Psychol, 2017; 42(2):232–244; doi: 10.1093/jpepsy/jsw039
16.
SchrawJM, Peckham‐GregoryEC, RabinKR, et al.Area deprivation is associated with poorer overall survival in children with acute lymphoblastic leukemia. Pediatr Blood Cancer, 2020; 67(9):e28525; doi: 10.1002/pbc.28525
17.
AguirreAO, LimJ, BaigAA, et al.Association of Area Deprivation Index (ADI) with demographics and postoperative outcomes in pediatric brain tumor patients. Childs Nerv Syst, 2024; 40(1):79–86; doi: 10.1007/s00381-023-06098-6
18.
HarveyRC, MullighanCG, ChenI-M, et al.Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. Blood, 2010; 115(26):5312–5321; doi: 10.1182/blood-2009-09-245944
19.
BeaucheminMP, SolomonS, GallagherKD, et al.Feasibility of screening for and matching adolescents and young adults with cancer to a community-partnered financial and health-related social needs navigation intervention. JCO Oncol Pract, 2023; 19(suppl 11):281–281; doi: 10.1200/OP.2023.19.11_suppl.281
20.
MarkeyC, BelloO, HanleyM, et al.The use of area-level socioeconomic indices in evaluating cancer care delivery: A scoping review. Ann Surg Oncol, 2023; 30(5):2620–2628; doi: 10.1245/s10434-023-13099-x
